Recent Winners


+180%
PLX
Alert Price: $0.36
High Price: $1.01
Results: 180% in 40 Days
+157%
OREX
Alert Price: $1.81
High Price: $4.65
Results: 157% in 36 Days
+87%
ARIA
Alert Price: $12.72
High Price: $23.75
Results: 87% in 20 Days
+58%
XGTI
Alert Price: $1.47
High Price: $2.32
Results: 58% in 29 Days
+36%
CYNO
Alert Price: $48.25
High Price: $65.90
Results: 36% in 28 Days
+32%
EBS
Alert Price: $27.22
High Price: $35.88
Results: 32% in 6 Days
+27%
ICHR
Alert Price: $13.40
High Price: $17.04
Results: 27% in 22 Days
+23%
CNAT
Alert Price: $4.43
High Price: $5.45
Results: 23% in 3 Days
+23%
PEIX
Alert Price: $8.30
High Price: $10.25
Results: 23% in 12 Days
+21%
KATE
Alert Price: $15.40
High Price: $18.67
Results: 21% in 11 Days
+20%
REPH
Alert Price: $6.89
High Price: $8.25
Results: 20% in 11 Days
+20%
SN
Alert Price: $11.24
High Price: $13.46
Results: 20% in 15 Days
+16%
CX
Alert Price: $7.97
High Price: $9.30
Results: 16% in 10 Days
+16%
ACAD
Alert Price: $32.03
High Price: $37.09
Results: 16% in 26 Days
+15%
PVG
Alert Price: $7.17
High Price: $8.24
Results: 15% in 6 Days
+12%
OCLR
Alert Price: $8.49
High Price: $9.55
Results: 12% in 7 Days
+12%
ACET
Alert Price: $19.50
High Price: $21.93
Results: 12% in 26 Days
+12%
COW
Alert Price: $20.00
High Price: $22.42
Results: 12% in 26 Days
+11%
PLKI
Alert Price: $70.82
High Price: $79
Results: 11% in 5 Days
+10%
HWKN
Alert Price: $48.15
High Price: $52.90
Results: 10% in 14 Days
+9%
LLY
Alert Price: $67.61
High Price: $73.56
Results: 9% in 12 Days

Past results are not indicative of future profits. This table is accurate, though not every trade is represented.

jb2


Top Catalysts For The Week Ending February 17 2017


LightPath Technologies = Beats on earnings and revenue

Editas Medicine = Patent Office Decision Favorable to Broad Institute in CRISPR

Agilent Technologies = Beats on Earnings and Revenue

IPG Photonics = Beats on earnings and revenue

Sonus Networks = Rising Money Flow On Institutional Buying

KapStone Paper = Confirms Raising Containerboard Prices

Popeyes Louisiana Kitchen = Hearing Takeover Rumors Circulating

XPO Logistics = Rising Revenue and Money Flow

jb-vertical


Trading Lessons

Mainstream Financial News

Archives

Lannett Beats On Earnings and Revenue

Follow Us on StockTwits

February 01, 2017: Lannett Company reports Q2 EPS of $0.92 versus the $0.83 estimate. Revenue also beat coming in at $170.9 million versus the $169 million estimate.

The CEO said, “Higher sales across a number of products and the addition of KU’s operations were key drivers to the 35% increase in our fiscal 2017 second quarter net sales… Our outlook for the current fiscal year remains strong. During the quarter, we received several product approvals and continued to make excellent progress integrating KU’s operations and consolidating our manufacturing, sales, R&D and distribution functions. And more recently, we voluntarily paid down $75 million of debt, lowering our annualized cash interest expense by approximately $4 million, and our board of directors approved a plan to invest in our pain management facilities, which will significantly increase our active pharmaceutical ingredients (APIs) production and bolster our efforts to vertically integrate.”

January 3, 2016: Lannett received approval last week from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Lopinavir and Ritonavir Oral Solution USP, 80 mg/20 mg per mL, the therapeutic equivalent to the reference listed drug, KaletraOral Solution of AbbVie Inc. Lannett, the first applicant to file a substantially complete ANDA for Lopinavir and Ritonavir Oral Solution USP, 80 mg/20 mg per mL with a Paragraph IV certification, may be eligible for 180 days of generic drug marketing exclusivity for the product, although the FDA has not made a final determination at this time.

The CEO said, “Lopinavir and Ritonavir Oral Solution, indicated for HIV-1 infections, represents the twelfth product approval we received in calendar 2016 and extends our line of oral generic drugs. This approval comes from our wholly owned subsidiary, Silarx Pharmaceuticals, which we acquired nearly 18 months ago to diversify our manufacturing capabilities and differentiate our product offering. I commend our entire regulatory team for the approval of this first-to-file, Paragraph IV product. We anticipate launching our product shortly.”

I predict a future trend of increased ANDA approvals from the FDA including legislation that will lean in favor of generic drug companies like Lannett in response to the practice by some pharmaceutical companies of buying older drugs, then jacking up the price to astronomical levels.

December 19, 2016: Lannett announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Supplemental New Drug Application (sNDA) for Morphine Sulfate Oral Solution CII, color and flavor added, 20 mg/mL. According to IMS, total U.S. sales for the 12 months ended October 2016 of Morphine Sulfate Oral Solution, at Average Wholesale Price (AWP) were approximately $22 million.

Morphine Sulfate Oral Solution is an opioid agonist indicated for the management of acute and chronic pain in opioid-tolerant patients severe enough to require an opioid analgesic and for which alternative treatments are inadequate.

November 28, 2016: Lannett announced that it received approval from the U.S. Food and Drug Administration (FDA) of its Abbreviated New Drug Application (ANDA) for Metaxalone Tablets USP, 800 mg, the therapeutic equivalent to the reference listed drug, Skelaxinof King Pharmaceuticals, Inc. According to IMS, total U.S. sales for the 12 months ended September 2016 of Metaxalone Tablets USP, 800 mg, at Average Wholesale Price (AWP) were approximately $173 million.

Lannett Stock Chart


The Finviz screener settings used to find Lannett are: Forward P/E Under 10, EPS growth past 5 years Over 30%, Sales growth past 5 years Over 30%, Sales growth qtr over qtr Over 30%, Institutional Transactions Positive (>0%)

Lannett Company, founded in 1942, develops, manufactures, packages, markets and distributes generic pharmaceutical products for a broad range of medical indications.

Fox Business’ Maria Bartiromo interviewed Lannett Company CEO Arthur Bedrosian back on December 23, 2015.

Trading The News: Lannett In The News